rh1

RH1 (NSC 697726) is a bioreductive anticancer compound that exhibits dose-dependent biphasic effects in vitro, inducing apoptosis at higher doses and senescence at lower doses.

Ginsenoside Rh1 (Sanchinoside B2) , one of the main constituents of Panax ginseng, exhibits anti-inflammatory effect.

(20R)-Ginsenoside Rh1 (20(R)-Ginsenoside Rh1) can inhibit the thrombin-induced conversion of fibrinogen to fibrin.

(20R)-Ginsenoside Rh1 (Standard) is a reference standard for research and analysis in studies involving (20R)-Ginsenoside Rh1. (20R)-Ginsenoside Rh1 (20(R)-Ginsenoside Rh1) can inhibit the thrombin-induced conversion of fibrinogen to fibrin.

20(E)-Sanchinoside B1 (Standard) is a reference standard for research and analysis in studies involving 20(E)-Sanchinoside B1. 20(E)-Sanchinoside B1 is a triterpenoid compound.

Ginsenoside Rh1 (Standard) is a reference standard for research and analysis in studies involving Ginsenoside Rh1. Ginsenoside Rh1 (Sanchinoside B2) , one of the main constituents of Panax ginseng, exhibits anti-inflammatory effect.

KRH102140 is a PHD2 activator that reduces angiogenesis by inhibiting HIF-1alpha, used in cardiovascular disease research.

RH1115 is a modulator of autophagolysosomes. It induces changes in the characteristics of LAMP1 vesicles and alters lysosomal localization.

RH12 is a dual inhibitor of SARS-CoV-2-related RNA-dependent RNA polymerase (RdRp, IC50 of 4.42 nM) and human transmembrane serine protease 2 (TMPRSS2, IC50 of 4.2 nM). It demonstrates antiviral activity by inhibiting viral replication and absorption, showing 90.5% virucidal effect in Vero-E6 cells. Additionally, RH12 inhibits Calu-3 cell viability with an IC50 of 17.5 nM.

KRH102053 is a HIF-1alpha inhibitor. KRH102053 decreased the protein level of HIF-1alpha and the mRNA levels of HIF-regulated downstream target genes, such as vascular endothelial growth factor, aldolase A, enolase 1 and monocarboxylate transporter 4. Consistent with these results, KRH102053 also inhibited the rates of HIF-related migration and invasion of HOS cells as well as the degree of tube formation in human umbilical vein endothelium cells.

D-Leu-Pro-Arg-Rh110-D-Pro serves as a substrate for Factor XaI (FXIa) and exhibits binding affinity. This compound is composed of Rhodamine 110 linked to a peptide chain via a cleavable bond. Upon cleavage, the intensity of the fluorophore is enhanced. D-Leu-Pro-Arg-Rh110-D-Pro can be utilized to detect FXIa activity.

D-Leu-Pro-Arg-Rh110-D-Pro TFA is a substrate for Factor XaI (FXIa) known for its binding affinity. It consists of Rhodamine 110 linked to a peptide chain through a cleavable bond. The cleavage of this bond enhances the intensity of the fluorophore. D-Leu-Pro-Arg-Rh110-D-Pro TFA can be utilized to detect FXIa activity.

D-Leu-Pro-Arg-Rh110-D-Pro acetate is a substrate for Factor XaI (FXIa) with binding affinity. This compound is formed by linking Rhodamine 110 to a peptide chain via a cleavable bond. The cleavage of this bond enhances the intensity of the fluorophore. D-Leu-Pro-Arg-Rh110-D-Pro acetate can be used to detect FXIa activity.

(Z-AR)2Rh110 is a derivative of Rhodamine. It can be hydrolyzed by trypsin.

(Z-Asp-Glu-Val-Asp)2-Rh110 is a reagent used in biochemical reactions.

RJW100 is a compound that acts as a potent agonist of liver receptor homolog 1 (LRH-1, NR5A2) and steroidogenic factor-1 (SF-1, NR5A1), exhibiting pEC50 values of 6.6 and 7.5, respectively. Additionally, RJW100 induces robust activation of the miR-200c (miRNA-200c, microRNA-200c) promoter.

(Iso)-RJW100 is a potent liver receptor homolog 1 (LRH-1, NR5A2) and steroidogenic factor-1 (SF-1, NR5A1) agonist with pEC 50 s of 6.4 and 7.2, respectively.

LRH-1 Inhibitor-3 is an antagonist that inhibits LRH-1 transcriptional activity, reducing the expression of target genes associated with cell growth and proliferation, such as SHP (small heterodimer partner), cyclin E1 (CCNE1), and G0S2, and inhibiting the proliferation of human pancreatic, colon, and breast adenocarcinoma cells.

Doxepin-D3 hydrochloride is a deuterium-labeled, stable isotope-labeled analogue of doxepin hydrochloride, primarily used as an internal standard for quantitative analysis. Doxepin hydrochloride (T1540) is a tricyclic antidepressant (TCA) and uesd for treating depression, anxiety, and insomnia.

ML-180 (SR1848) is a potent inverse agonist of the orphan nuclear receptor liver receptor homolog 1 (LRH-1; NR5A2) with an IC50 of 3.7 μM.

PARP14 inhibitor H10 is a selective inhibitor against PARP14 with IC50 of 490 nM

LRH-1 agonist-1 (compound 74) acts as an agonist for LRH-1, exhibiting an IC50 value of 47 μM.

LRH-1 antagonist-1 (Compound 3d2) is an LRH-1 antagonist with a Kd of 1.8 μM. It inhibits LRH-1 transcriptional activity and reduces G0S2 expression. Additionally, LRH-1 antagonist-1 suppresses the proliferation of LRH-1 positive cancer cells and can be utilized for research in pancreatic, colon, and breast cancers.

LRH-1 antagonist-1 (Compound 3d2) dihydrochloride is an LRH-1 antagonist with a Kd of 1.8 μM. It inhibits LRH-1 transcriptional activity and reduces G0S2 expression. Additionally, LRH-1 antagonist-1 dihydrochloride suppresses the proliferation of LRH-1 positive cancer cells and can be utilized in the study of pancreatic, colon, and breast cancers.